Spirometry as a motivator for smoking cessation among patients attending the smoking cessation clinic of Monastir.
Motivation
Smoking Cessation
Spirometry
Tunisia
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
10 06 2022
10 06 2022
Historique:
received:
28
12
2021
accepted:
02
06
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
15
6
2022
Statut:
epublish
Résumé
The choice of spirometry, a biomarker of lung health, as a motivator for smoking cessation is based on its fidelity in emphasizing tobacco adverse effects. Yet, there is a paucity of evidence on its efficacy, and the findings are currently inconclusive. The aim of this study was to determine whether a spirometry and lung age communication has an effect on smoking cessation rates. We conducted a randomized controlled trial among patients who attended the smoking cessation clinic (SCC) at Fattouma Bourguiba University Hospital in Monastir, from June 2017 to February 2020. Participants were assigned into two groups, a control arm receiving standard program and intervention arm receiving a spirometry and lung age announcement along with usual care. The primary outcomes were the smoking cessation rates after one year of follow-up between the intervention arm and the control arm. At one-year endpoint, a total of 456 were reachable for assessment, 236 in control group and 220 in spirometry group, which leads to a loss rate equal to 8.8%. One-year smoking cessation rate was higher among the intervention group than among control group (25.5% versus 16.5%), with a considerable statistical significance (p = 0.019). Lung age was significantly higher at paired comparison with chronological age. Smoking cessation is still a challenging procedure with a high risk of relapse, making very valuable any approach that may increase motivation in both unmotivated and motivated smokers. This study is an additional evidence for spirometry and lung age announcement as motivators for smoking cessation. Pan African Clinical Trial Registry database ( PACTR202110595729653 ), 06/10/ 2021.
Sections du résumé
BACKGROUND
The choice of spirometry, a biomarker of lung health, as a motivator for smoking cessation is based on its fidelity in emphasizing tobacco adverse effects. Yet, there is a paucity of evidence on its efficacy, and the findings are currently inconclusive. The aim of this study was to determine whether a spirometry and lung age communication has an effect on smoking cessation rates.
METHODOLOGY
We conducted a randomized controlled trial among patients who attended the smoking cessation clinic (SCC) at Fattouma Bourguiba University Hospital in Monastir, from June 2017 to February 2020. Participants were assigned into two groups, a control arm receiving standard program and intervention arm receiving a spirometry and lung age announcement along with usual care. The primary outcomes were the smoking cessation rates after one year of follow-up between the intervention arm and the control arm.
RESULTS
At one-year endpoint, a total of 456 were reachable for assessment, 236 in control group and 220 in spirometry group, which leads to a loss rate equal to 8.8%. One-year smoking cessation rate was higher among the intervention group than among control group (25.5% versus 16.5%), with a considerable statistical significance (p = 0.019). Lung age was significantly higher at paired comparison with chronological age.
CONCLUSION
Smoking cessation is still a challenging procedure with a high risk of relapse, making very valuable any approach that may increase motivation in both unmotivated and motivated smokers. This study is an additional evidence for spirometry and lung age announcement as motivators for smoking cessation.
TRIAL REGISTRATION
Pan African Clinical Trial Registry database ( PACTR202110595729653 ), 06/10/ 2021.
Identifiants
pubmed: 35689178
doi: 10.1186/s12889-022-13583-1
pii: 10.1186/s12889-022-13583-1
pmc: PMC9185973
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1164Informations de copyright
© 2022. The Author(s).
Références
Nicotine Tob Res. 2007 Jan;9(1):21-32
pubmed: 17365733
BMC Fam Pract. 2016 Feb 04;17:15
pubmed: 26846522
Scand J Prim Health Care. 2006 Sep;24(3):133-9
pubmed: 16923621
Eur Respir J. 2009 Apr;33(4):754-62
pubmed: 19129277
Pharmacotherapy. 2018 Feb;38(2):235-258
pubmed: 29250815
JAMA. 1992 Nov 18;268(19):2687-94
pubmed: 1304736
Drug Alcohol Depend. 2015 Sep 1;154:14-24
pubmed: 26094185
Addict Health. 2016 Winter;8(1):1-8
pubmed: 27274787
Respir Med. 2006 Nov;100(11):2012-7
pubmed: 16580189
Rev Pneumol Clin. 2018 Jun;74(3):160-169
pubmed: 29650283
Med Clin North Am. 1992 Mar;76(2):451-76
pubmed: 1548971
Patient Educ Couns. 2010 Aug;80(2):280-3
pubmed: 20434863
Sci Rep. 2017 Nov 13;7(1):15462
pubmed: 29133917
Nicotine Tob Res. 2012 Aug;14(8):891-9
pubmed: 22249687
J Fam Pract. 2008 Sep;57(9):584-6
pubmed: 18786330
Rev Mal Respir. 2017 Sep;34(7):734-741
pubmed: 28209422
Int J Adolesc Med Health. 2016 May 1;28(2):211-6
pubmed: 26360487
J Adv Nurs. 2015 Oct;71(10):2426-34
pubmed: 25996459
Ann Intern Med. 2006 Dec 5;145(11):845-56
pubmed: 16954352
Nicotine Tob Res. 2011 Nov;13(11):1161-6
pubmed: 21551248
Tob Induc Dis. 2019 Apr 17;17:31
pubmed: 31516474
J Gen Intern Med. 1990 Jan-Feb;5(1):16-22
pubmed: 2405112
BMJ. 2009 Apr 02;338:b1024
pubmed: 19342408
Cancer Causes Control. 1991 Jul;2(4):239-46
pubmed: 1873454
Respir Care. 2008 Sep;53(9):1217-22
pubmed: 18807274
BMC Fam Pract. 2013 Dec 05;14:185
pubmed: 24308728
BMJ. 2008 Mar 15;336(7644):598-600
pubmed: 18326503
J Epidemiol Community Health (1978). 1978 Dec;32(4):275-81
pubmed: 370171
J Gen Intern Med. 1999 Nov;14(11):670-6
pubmed: 10571715
J Thorac Dis. 2017 Dec;9(12):5052-5060
pubmed: 29312710
Am J Public Health. 1994 Jul;84(7):1086-93
pubmed: 8017530